Cargando…

Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer

INTRODUCTION: Exemestane was approved in 2005 for adjuvant treatment of breast cancer. In this study, we aimed to assess whether it is cost-effective in comparison to available alternatives. MATERIAL AND METHODS: To evaluate the efficacy of exemestane, a systematic review was conducted by searching...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hashemi-Meshkini, Amir, Keshavarz, Khosro, Gharibnaseri, Zahra, Kheirandish, Mehrnaz, Kebriaeezadeh, Abbas, Nikfar, Shekoufeh, Abdollahi, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2013
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701982/ https://www.ncbi.nlm.nih.gov/pubmed/23847669 http://dx.doi.org/10.5114/aoms.2013.35347

Ejemplares similares

A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience
por: Keshavarz, Khosro, et al.
Publicado: (2013)

Pharmacists Remuneration Models in Iran and Selected Countries: a Comparative Study
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

Financial perspective of private pharmacies in Tehran (Iran); is it a lucrative business?
por: Keshavarz, Khosro, et al.
Publicado: (2012)

Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies
por: Rezvanfar, Mohammad Ali, et al.
Publicado: (2013)

Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children
por: Gharibnaseri, Zahra, et al.
Publicado: (2012)

A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model
por: Keshavarz, Khosro, et al.
Publicado: (2016)

Is Taurolidine-citrate an effective and cost-effective hemodialysis catheter lock solution? A systematic review and cost- effectiveness analysis
por: Kavosi, Zahra, et al.
Publicado: (2016)

Assessment of the vaccine industry in Iran in context of accession to WTO: a survey study
por: Hashemi Meshkini, Amir, et al.
Publicado: (2012)

Direct and indirect cost of managing Alzheimer’s disease in the Islamic Republic of Iran
por: Aajami, Zahra, et al.
Publicado: (2019)

A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
por: Alavian, Seyed Moayed, et al.
Publicado: (2016)

From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2014)

Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran
por: Nikfar, Shekoufeh, et al.
Publicado: (2005)

Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials
por: Keshavarz, Khosro, et al.
Publicado: (2017)

A model for developing a decision support system to simulate national drug policy indicators
por: Abdollahiasl, Akbar, et al.
Publicado: (2011)

Evaluation of COVID-19 Treatments in Iran in Comparison with Local Therapeutic Recommendations: A Population-Level Study on Utilization and Costs of Prescription Drugs
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2022)

Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

Consistent defined threshold and equity in health
por: Nikfar, Shekoufeh, et al.
Publicado: (2015)

A Scoping Review of Different Methods of Assessing the Impact of New Medical Technologies at Early Stages of Development
por: Goudarzi, Zahra, et al.
Publicado: (2021)

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2018)

A review on inputs and outputs in determining the efficiency of universities of medical sciences by data envelopment analysis method
por: Mojahedian, Mohammad M., et al.
Publicado: (2020)

Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2023)

A system dynamics model for national drug policy
por: Abdollahiasl, Akbar, et al.
Publicado: (2014)

Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
por: Keshavarz, Khosro, et al.
Publicado: (2015)

Cost-utility of Protocols of BFM-ALL and UK-ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran
por: HAYATI, Hadi, et al.
Publicado: (2018)

A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease
por: Ehteshami-Afshar, Solmaz, et al.
Publicado: (2011)

Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran
por: Teimouri, Fatemeh, et al.
Publicado: (2017)

Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries
por: Kebriaeezadeh, Abbas, et al.
Publicado: (2013)

Pattern of Antidepressant Utilization and Cost in Iran from 2006 to 2013 in Comparison with Other Countries
por: Soleymani, Fatemeh, et al.
Publicado: (2018)

Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Social accounting matrix and the effects of economic reform on health price index and household expenditures: Evidence from Iran
por: Keshavarz, Khosro, et al.
Publicado: (2017)

Pharmaceutical market and health system in the Middle Eastern and Central Asian countries: Time for innovations and changes in policies and actions
por: Abdollahias, Akbar, et al.
Publicado: (2011)

The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis
por: Rezaie, Ali, et al.
Publicado: (2010)

Are probiotics effective in management of irritable bowel syndrome?
por: Hosseini, Asieh, et al.
Publicado: (2012)

Current opinion on treatment of inflammatory bowel disease in pregnant women
por: Salari, Pooneh, et al.
Publicado: (2012)

Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients
por: Mozaffari, Shilan, et al.
Publicado: (2014)

Achieving Equitable Access to Medicines and Health Services: A COVID-19-time Recalled Matter
por: Mousavi, Taraneh, et al.
Publicado: (2021)

Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Goudarzi, Zahra, et al.
Publicado: (2023)

Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

A Systematic Review of Discrete Choice Experiment Studies in Rheumatoid Arthritis Biological Medicines
por: Zartab, Saman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_djtem2hjg0q1p9e3sq37a73234